Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 41, Issue 2, Pages 437-449Publisher
WILEY
DOI: 10.1002/eji.201040429
Keywords
Complement; Multiple myeloma; Serglycin
Categories
Funding
- Swedish Cancer Foundation
- Swedish Research Council
- Swedish Foundation for Strategic Research
- Foundations of Osterlund
- Kock, King Gustav V's 80th Anniversary Foundation
- Knut and Alice Wallenberg's, Inga-Britt and Arne Lundberg
- University Hospitals in Malom
Ask authors/readers for more resources
Serglycin (SG) is a proteoglycan expressed by hematopoietic cells and is constitutively secreted by multiple myeloma (MM) cells. SG participates in the regulation of various inflammatory events. We found that SG secreted by human MM cell lines inhibits both the classical and lectin pathways of complement, without influencing alternative pathway activity. The inhibitory effect of SG is due to direct interactions with C1q and mannose-binding lectin (MBL). C1q-binding is mediated through the glycosaminoglycan moieties of SG, whereas MBL binds additionally to SG protein core. Interactions between SG and C1q as well as MBL are diminished in the presence of chondroitin sulfate type E. In addition, we localized the SG-binding site to the collagen-like stalk of C1q. Interactions between SG and C1q as well as MBL are ionic in character and only the interaction with MBL was found to be partially dependent on the presence of calcium. We found the serum levels of SG to be elevated in patients with MM compared to healthy controls. Moreover, we found that SG expressed from myeloma plasma cells protects these cells from complement activation induced by treatment with anti-thymocyte immunoglobulins. This might protect myeloma cells during immunotherapy and promote survival of malignant cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available